Tirzepatide

Common questions about Tirzepatide

What is tirzepatide?

Tirzepatide is a once-weekly dual agonist that activates both the GIP and GLP-1 receptors. It is studied for type-2 diabetes and obesity and is approved clinically under the brand names Mounjaro and Zepbound in many jurisdictions.

Is tirzepatide FDA-approved?

Yes — under the brand names Mounjaro (type-2 diabetes) and Zepbound (chronic weight management). The unbranded research-grade compound distributed by peptide vendors is not the FDA-approved finished product and is intended for research use only.

What is the half-life of tirzepatide?

Published pharmacokinetic studies report a half-life of approximately 5.4 days, supporting the once-weekly clinical dosing schedule.

What dose of tirzepatide is used in research?

Clinical protocols use graduated dose escalation over several weeks. Pepticker does not publish a dosing recommendation — refer to the prescribing information or the original peer-reviewed study you are reproducing.

How is tirzepatide different from semaglutide?

Tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is a single GLP-1 agonist. Head-to-head clinical trials (notably SURPASS-2) have reported larger weight-loss and HbA1c reductions for tirzepatide at comparable timepoints.

Is tirzepatide legal to buy as a research compound?

In the US, Canada, and the UK research-chemical vendors supply the unbranded compound; clinical use requires a prescription. In Australia it is TGA Schedule 4 and prescription-only when used clinically. Status is informational — not legal advice.

Editorial summary of published research. Not medical advice. See /methodology for sourcing.